Ravi Viswanathan, 10% Owner at Adaptimmune Therapeutics PLC (ADAP), bought 15,000,000 shares at $1.67 ($25.1M) on 2018-09-07, disclosed to the SEC on 2018-09-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.67 | 3,000,000 | $5.0M | 20.0% |
| 2 | $1.67 | 12,000,000 | $20.0M | 80.0% |
| Total | $1.67 avg | 15,000,000 | $25.1M | 100% |
| Filing → |
| AVEO | BUY | 2018-06-28 | $404K | — | Filing → |
| AVEO | BUY | 2018-05-30 | $591 | — | Filing → |
| AVEO | BUY | 2018-05-21 | $897K | — | Filing → |